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INTRODUCTION 
Elderly are vulnerable to electrolyte disturbances, hyponatremia 
being the commonest disorder in the aged population [1]. It is defined as 
plasma sodium level below 135 mEq/litre. Many studies show that 
hyponatremia is prevalent in the hospitalized patients in around 20 
percent. Incidence of hyponatremia is higher among elderly, when 
compared to young adults. This is attributed to the fact that, when elderly 
persons are exposed to a change in environment and an altered dietary 
practice, there is impairment in their ability to maintain an optimal 
balance of water and electrolytes [2]. 
Factors contributing to the development of hyponatremia in the 
elderly patients include an age associated decrease in free water excretion 
and glomerular filtration rate (GFR). Aging is associated with increased 
loss of sodium in urine. This is contributed by decreased action of renin 
angiotensin aldosterone system (RAAS) and exaggerated action of 
natriuretic hormones. 
Development of severe hyponatremia is associated with high 
morbidity and mortality. This is especially so in elderly patients. Hence 
identification and assessment of different types of hyponatremia in 
elderly patient is very important to improve the patient outcome. The 
etiology of hyponatremia among geriatric age group is complex and it is 
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further complicated by an unclear relationship between arginine 
vasopressin and advancing age 
There are different types of hyponatremia based on the volume 
status of the individual. They are 
1. Euvolemic hyponatremia 
2. Hypervolemic hyponatremia 
3. Hypovolemic hyponatremia 
Particularly in hospital setting with acute medical problems, the 
recognition of different types of hyponatremia and appropriate clinical 
intervention is critical for improving patient outcomes. Data regarding the 
prevalence and different types of hyponatremia in elderly in our country 
is limited. 
History and clinical examination including  assessment of volume 
status, measuring serum osmolality, serum sodium and urinary sodium 
concentrations is essential to differentiate the types of hyponatremia and 
to detect the possible etiological factor responsible for hyponatremia and 
to determine the most appropriate treatment. 
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AIMS OF THE STUDY 
1. To identify the prevalence of hyponatremia in hospitalized elderly 
patients above 65 years of age. 
2. To study the clinical presentation of hyponatremia in elderly. 
3. To identify the types and etiological factors of hyponatremia. 
  
4 
 
REVIEW OF LITERATURE 
Hyponatremia is defined as plasma sodium below 135 mEq/litre. 
This results from an increase in circulating arginine vasopressin and 
increased renal sensitivity to arginine vasopressin, combined with free 
water intake. Homeostatic system regulating water and electrolyte 
balance undergoes various changes with age. The confluence of aging, 
associated medical conditions, multiple drug intake, varied oral intake, 
results in water and electrolyte abnormalities in the elderly. 
PREVALENCE: 
Hyponatremia is the most common electrolyte abnormality in 
geriatric age group [4]. Prevalence of hyponatremia in chronic care 
facilities is 15 to 18 percent [5]. Studies suggest a one percent prevalence 
of hyponatremia in nursing home residents.[6]. A study conducted by 
Gill’s et al showed a mortality of 28 percent when plasma sodium falls 
below 125 mEq/litre [7].  It is said that the prevalence of hyponatremia is 
18 percent in a study conducted among nursing home resident [8]. When 
these residents are observed over a period of one year ,53 percent of the 
observed experienced one or more episodes of hyponatremia [8] 
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BODY COMPOSITION OF FLUIDS: 
About 55 to 65 percent of body weight is constituted by total body 
water [TBW]. Total body water is divided and distributed into 
intracellular [ICF] and extracellular [ECF] fluid compartment. 55 to 75 
percent of total body water is in ICF and 25 to 45 percent is in ECF. ECF 
is subdivided into intravascular and interstitial fluid in the ratio of 
1:3.That is 75 percent of ECF is in interstitial fluid and 25 percent is in 
intravascular compartment. Sodium is primarily an extracellular cation 
and potassium is primarily an intracellular cation.  
EFFECTS OF AGING IN BODY COMPOSITION: 
Normal aging is associated with a decrease in total body water, 
decrease in muscle mass and there is higher fat mass. Thus, TBW 
declines approximately from 60 percent of body weight to 53 percent in 
men older than age of 65 years when compared to young adults. TBW in 
women older than age of 65 years decreases from 52 percent of body 
weight to 45 percent when compared to young adults. This is mainly due 
to decline in ICF. This decrease in TBW may place the elderly patient at 
risk of hyponatremia. 
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WATER HOMEOSTASIS: 
The maintenance of normal water balance is achieved through the 
combined action of three main factors: vasopressin, the kidney, and thirst 
mechanism.  Equal amount of water intake and water loss is required for 
maintenance of water balance. Secretion of adequate quantities of 
osmotically stimulated vasopressin is needed, which must be able to bind 
to the renal tubule to modulate the flow of solute-free water and produce 
antidiuresis. Daily loss of water from an extra renal route is 
approximately 500ml. Daily loss of water from kidney depends on 
urinary solute excretion. Most healthy adults usually ingest 1.5 to 2.5 L of 
water per day and excrete 1 to 2 litres of urine per 24 h, but the normal 
kidney is capable of wide variation in urine output. Osmotically 
stimulated thirst must be able to promote drinking and is particularly 
important when the kidney is concentrating urine maximally. 
Persistent water loss can occur from excessive sweating due to 
fever, exercise, hot climate or copious watery diarrhoea. Under these 
circumstances water homeostasis cannot be maintained without adequate 
fluid intake. The increase in serum osmolality due to this extrarenal water 
loss activates thirst centers and favours arginine vasopressin secretion. 
This promotes water intake and conserves water loss through kidney 
leading to restoration of water balance and maintaining a normal serum 
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osmolality. Fine control of water balance ensures that the concentration 
of solutes, particularly extracellular sodium, remains stable. These factors 
allows plasma osmolality to be maintained within the narrow range 285 
to 295 mosm/kg of water  in healthy adults. 
ROLE OF THIRST IN WATER BALANCE: 
Thirst is the defence mechanism to promote water intake in 
response to loss of body water. It is defined as consciously perceived 
desire for water. True thirst must be distinguished from other 
determinants of fluid intake such as taste, dietary preferences, and social 
customs. Hyperosmolality is the potent stimulus for thirst. Stimulus for 
thirst arises when serum osmolality is raised above 290 mosm/kg of 
water. Thirst centres are located in anterior hypothalamus. Hypovolemia 
stimulates renin angiotensin aldosterone system [RAAS], angiotensin II 
reaching the hypothalamus stimulates the thirst by potent dipsogenic 
effect [9]. Other factors affecting thirst are dry mouth and social 
influences. 
AGING IMPACT ON THIRST: 
Healthy persons older than 65 years have shown an age associated 
impairment in thirst perception. The presence of physical disabilities like 
blindness, stroke, arthritis limit the elderly from access to fluids, which 
further confounds the elderly to ingest adequate amount of fluids. 
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ROLE OF VASOPRESSIN IN WATER HOMEOSTASIS: 
Hypothalamus synthesizes arginine vasopressin and it is secreted 
by neurohypophysis. It is cleared by liver and kidney. Its t½ is about 20 
minutes. In persons older than age of 60 years, there is an increase in size 
of para ventricular and supra optic nuclei of hypothalamus. This suggests 
that arginine vasopressin secretion increases as persons get old. 
REGULATION OF VASOPRESSIN SECRETION: 
Hyperosmolality and decreased ECF volume or arterial blood 
pressure stimulates arginine vasopressin secretion from neurohypophysis 
[10]. Arginine vasopressin secretion promotes water conservation by the 
kidney. This corrects hyperosmolality and corrects hypovolemia and 
arterial pressure. Hypoosmolality decreases arginine vasopressin 
secretion, which causes water loss and promotes a negative fluid balance 
and brings back plasma osmolality to normal. Volume expansion has 
little effect on vasopressin release. 
OSMOLALITY: 
Circulating vasopressin is undetectable when serum osmolality is 
less than 280mosm/kg of water in normal individuals. The  magnocellular 
neurons  have been found to have intrinsic osmoreceptive properties[11], 
but several research  shows that the most sensitive osmoreceptive cells 
that are able to sense small changes in plasma osmolality and transduce 
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these changes into arginine vasopressin secretion are found  in the 
hypothalamus in  circumventricular organ called organum vasculosum of 
the lamina terminalis (OVLT) .The strongest evidence for location of the 
primary osmoreceptors in this area of the brain are the multiple studies 
that have demonstrated that destruction of this area disrupts osmotically 
stimulated arginine vasopressin  secretion and thirst without affecting the 
neurohypophysis or its response to nonosmotic stimuli [12][13]. The 
osmoreceptors found in hypothalamus are very sensitive to disturbances 
in plasma osmolality. Even a small change of one percent is sensed by 
osmoreceptors. This is responsible for the stability of plasma osmolality. 
Because of these the serum osmolality does not fluctuate more than 1 to 2 
percent despite wide variation in water intake. The osmolality threshold 
for arginine vasopressin ranges from 280 to 290 mosm/kg of water. An 
increase in serum osmolality of one mOsm/kg of water favours an 
increase of arginine vasopressin about 0.4 to 1 picogram per millilitre. 
The response of kidney to arginine vasopressin in circulation is linear. 
Plasma sodium and other associated anions mainly determine plasma 
osmolality. Plasma Na
+
 is the main trigger for arginine vasopressin 
secretion. Ineffective osmoles cannot promote vasopressin secretion. 
Infusion of hypertonic saline or mannitol causes a rise in plasma 
osmolality .This favours the exit of water from osmoreceptor cells and 
leads to stimulation of these cells. In the opposite, ineffective osmole like 
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urea freely move in and out of cell membranes. This does not cause a rise 
in plasma osmolality. Glucose in normal individuals is an ineffective 
osmole. In patients with poor control of diabetes mellitus, glucose favours 
agrinine vasopressin secretion.  
 
ECF VOLUME AND BLOOD PRESSURE: 
A ten percent decrease in ECF volume is required to stimulate 
arginine vasopressin release. When the volume loss is greater it causes an 
exponential increase in arginine vasopressin in circulation [14]. 
Hypotension when severe, is a strong stimulant to arginine vasopressin 
secretion. Loss of blood volume enhances the effect of arginine 
vasopressin. It overcomes the inhibition of arginine vasopressin secretion 
caused by hypoosmolality. This concept is most important in 
hyponatremia associated with states of decreased effective circulatory 
volume. The hemodynamic influences on arginine vasopressin secretion 
are mediated partly by neural pathways from baroreceptors located in the  
atria, aorta, and carotid sinus. Afferent nerve fibers from these receptors 
rise via the vagus and glossopharyngeal nerves to the nuclei of the tractus 
solitarius (NTS) in the brainstem [15]. A variety of postsynaptic 
pathways from the NTS then project via the ventrolateral medulla and the 
lateral parabrachial nucleus, to the paraventricular and supraoptic nuclei 
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in the hypothalamus [16]. The pace at which the parasympathetic nerve 
discharges from baroreceptors in carotid sinus alters the action of 
vasomotor center located in the medulla. This favours the release of AVP 
from paraventricular nucleus [17]. Supraoptic nucleus takes part in AVP 
release caused by disturbances in plasma osmolality. Thus, increased 
discharge from these nerves in conditions like emesis, chronic liver 
disease, cardiac failure which are associated with low blood volume 
favours arginine vasopressin secretion. 
 
OTHER FACTORS REGULATING ARGININE VASOPRESSIN 
SECRETION: 
ORAL FLUID INTAKE: 
The peripheral neural sensors also affect the arginine vasopressin 
secretion in addition to the baroreceptors. Drinking lowers the plasma 
arginine vasopressin before decreasing plasma osmolality or serum 
sodium. Arginine vasopressin suppression in response to drinking is 
influenced by temperature of fluids. Because the suppression is greater 
when colder fluids are ingested by humans [18]. Sensory afferent 
originating in the oropharynx and transmission via glossopharyngeal 
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nerve is the pathway most likely responsible for this arginine vasopressin 
suppression due to drinking. 
NAUSEA: 
Nausea appears to be the most prominent non osmotic stimuli to 
arginine vasopressin secretion. The sensation of nausea, in the absence or 
presence of emesis, is the strongest stimulus to arginine vasopressin 
secretion known in humans. A twenty percent rise in osmolality increases 
arginine vasopressin  concentration to 5 to 20 picogram/millilitre. A 20 
percent decline in arterial pressure increases arginine vasopressin to 10 to 
100 picogram/millilitre. The sense to vomit has been reported to cause 
arginine vasopressin increase to the level of 200 to 400 
picogram/millilitre[19]. This action is mediated by chemoreceptor zone in 
area postrema in brainstem. Drugs and conditions which cause nausea 
favours arginine vasopressin release instantaneously and it is extremely 
potent. Emetic response directs number of  pharmacologic and pathologic 
actions  on arginine vasopressin secretion. This is responsible for increase 
in arginine vasopressin secretion associated with vasovagal reactions, 
diabetic ketoacidosis, motion sickness and acute hypoxia. 
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HYPOGLYCEMIA: 
Acute hypoglycaemia is also a stimulus for arginine vasopressin 
secretion. But it is a less potent stimulus when compared to nausea [20]. 
When glucose is decreased more than 20 percent of normal it can cause  
the release of arginine vasopressin. The rate at which the glucose level 
decreases is critical for stimulation of arginine vasopressin release. 
Because of persistent hypoglycaemia the rise in arginine vasopressin is 
not sustained [20]. This  glucopenic stimuli is of less  importance in the 
physiology or pathology of AVP secretion, because there are probably 
few drugs or conditions that lower plasma glucose rapidly enough to 
stimulate release of the hormone, and further this effect is transient. 
 
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM [RAAS]: 
The RAAS mediates the regulation of arginine vasopressin 
secretion [21].Angiotensin II stimulates arginine vasopressin secretion by 
acting at circumventricular subfornical organ in brain. This is a small 
anatomical structure found in the posterior aspect of IIIrd ventricle of 
brain. Because the circumventricular organs are outside the blood brain 
barrier, the receptors located in subfornical organ can detect even a little 
increase in angiotensin II levels in plasma [22]. Neural pathways from 
14 
 
subfornical organ reaches the supraoptic and paraventricular nuclei of 
hypothalamus and mediate arginine vasopressin secretion into circulation 
[23]. 
 
STRESS: 
Non specific stress caused by pain, emotion, physical exercise may 
cause arginine vasopressin secretion. 
But it is unknown whether this effect is a direct effect mediated by 
a specific pathway or secondary to low blood volume or vomiting 
sensation that is usually associated with vasovagal reactions accelerated 
by stress. Pain following trauma and surgery stimulates arginine 
vasopressin release from posterior pituitary. This when combined with 
post operative hypotonic fluid infusion and water intake promotes water 
retention and poses the patient at greater risk of dilutional hyponatremia. 
Arginine vasopressin release in response to pain and temperature is 
important because painful and febrile illness are associated with 
osmotically inappropriate secretion of the hormone. 
HYPOXIA AND HYPERCAPNIA: 
Acute hypoxia and hypercapnia also stimulates arginine 
vasopressin secretion into the circulation [24] [25]. It is unclear whether 
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there is a threshold for hypoxia to stimulate arginine vasopressin release. 
Several studies show that stimulation of arginine vasopressin secretion 
due to moderate hypoxia (>35 mm of Hg) is not consistent and if arginine 
vasopressin secretion occurs it seems to be mainly in those who develop 
nausea or low blood pressure. Severe hypoxia (<35 mm Hg) promotes 
arginine vasopressin release even without presence of nausea or 
hypotension. This suggests that there may be hypoxemic threshold for 
arginine vasopressin secretion. It is responsible for osmotically 
inappropriate arginine vasopressin release in patients with acute 
respiratory failure [26]. Hypercapnia also promotes the secretion of 
arginine vasopressin without the influence of hypoxia and hypotension. It 
is not known whether this response of arginine vasopressin secretion 
depends on threshold limit for hypercapnia. Mechanism behind the 
release of arginine vasopressin due to hypoxia and hypercapnia is 
unknown, but it may be due to peripheral chemoreceptor and 
baroreceptor. 
 
DRUGS AND HORMONES: 
Some of the drugs and hormones favouring the release of arginine 
vasopressin are 
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• Histamine, apomorphine, high doses of morphine, 
• Epinephrine , clofibrate, bradykinin,  
• Prostaglandin, acetylcholine ,vincristine, 2-deoxyglucose,insulin 
• Lithium, naloxone, nicotine,  cholecystokinin ,angiotensin II, 
• Carbamazepine, , isoproterenol chlorpropamide  
• Antidepressants and antipsychotics 
Some drugs and hormones inhibiting the arginine vasopressin 
release are 
• Norepinephrine, fluphenazine, haloperidol, promethazine 
• Butorphanol, opioid agonists, low doses of morphine, 
• Ethanol, carbamazepine, glucocorticoids, clonidine, 
• Phenytoin, phencyclidine, muscimol 
Vasopressor drugs like noradrenaline supresses AVP secretion 
indirectly by increasing blood pressure. Excitatory stimulants like 
cholecystokinin, isoproterenol , nicotine and high doses of morphine act 
by decreasing arterial pressure and inducing emesis. Carbamazepine 
suppresses arginine vasopressin release by decreasing osmotic sensitivity. 
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EFFECTS OF VASOPRESSIN: 
Arginine vasopressin actions are expressed by its interaction with 3 
different receptors which are coupled with G proteins. The V1a receptor 
favours the vasoconstrictive and proliferative action in smooth muscle 
cells of vascular system. It also promotes activation of coagulation by 
secretion of pro-coagulant factors like factor VIII and von Willebrand's 
factor from vascular endothelium and exaggerates aggregation of 
platelets. The V1b receptor confined to anterior pituitary cells, promotes 
the secretion of adrenocorticotropic hormone from anterior pituitary. 
Principal cells present in the cortical and medullary collecting duct of 
kidney contains V2 receptor on the basolateral membrane. This favours 
the water permeability by an AVP mediated action and permits osmotic 
equilibrium with interstitium of kidney[27]. Aginine vasopressin interacts 
with the V2 receptor and produces cyclic AMP by activation of adenyl 
cyclase. This cyclic AMP, a second messenger starts  a series of events 
that cause insertion of aquaporin-2 channels into the apical side of the 
principal cells located in collecting duct [28]. Water moves into the cells 
along the osmotic gradient with the help of this aquaporin-2. Water exits 
to the systemic circulation across the basolateral membrane rapidly 
through aquaporin-3. After the decline in arginine vasopressin action, the 
water channels are returned to the cytoplasm by endocytosis [29]. 
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Arginine vasopressin favours the formation of prostaglandin E2 and 
prostacyclin by kidney [30]. This prostaglandin decreases the water 
conservation and vascular effects of arginine vasopressin. So it prevents 
an excessive water conservation effect and maintains kidney perfusion 
[31]. 
DISTRIBUTION AND CLEARANCE: 
Arginine vasopressin concentration is determined by the difference 
between the rates of secretion from the posterior pituitary gland and 
removal of the hormone from the vascular compartment via metabolism 
and urinary clearance. Enzymatic processes by which the liver and kidney 
inactivate arginine vasopressin involve an initial reduction of the 
disulfide bridge followed by aminopeptidase cleavage of the bond 
between amino acid residues 1 and 2. The extent of further degradation 
and the peptide products that escape into plasma and urine are unknown. 
 NORMAL AGING AND AVP SYSTEM: 
NEUROHYPOPHYSEAL SYSTEM: 
There is no degeneration of  magnocellular neurons appreciated  
due to aging. Many studies say that there may be an age associated 
increase in size of the  nucleus producing arginine vasopressin. Thus it 
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seems that hypothalamic arginine vasopressin neurons do not decrease 
with age. Infact it may remain stable or increased with age. 
 
 
 ARGININE VASOPRESSIN LEVEL WITH AGING: 
In young adults, there exists a diurnal variation of AVP release, 
with greatest arginine vasopressin release at night. These variations seem 
to be associated to the sleep-wake pattern and not to the time of the day. 
The peak in arginine vasopressin release due to sleep is not present in 
most of the healthy geriatric age group. Low arginine vasopressin and 
absence of a clear diurnal variation seems to be the cause for frequent 
micturition during the night in some geriatric population [33]. Many 
studies suggest that arginine vasopressin concentrations are higher in 
normal geriatric persons than young adults. There may be an age 
associated gradual increase in arginine vasopressin levels. Circulating 
arginine vasopressin correlates with plasma osmolality in young adults 
but no correlation is seen with geriatric persons[34]. Some studies 
suggest that there may be gender differences on plasma arginine 
vasopressin concentration, suggesting a two time higher concentration of 
arginine vasopressin in elderly man when compared to women. An 
increase in arginine vasopressin level as the person age is not due to the 
changes attributable to aging as there is no difference in t1/2, distribution 
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and metabolism of arginine vasopressin in young and elderly persons. So 
this increased basal plasma arginine vasopressin in elderly is most 
probably due to central control system managing arginine vasopressin 
secretion. 
 
 
ARGININE VASOPRESSIN STIMULATION: 
Serum osmolality is identified as the most important stimulant for 
arginine vasopressin release. Studies say that any osmotic stimulus 
promotes higher secretion of arginine vasopressin in geriatric persons 
when compared to young. This indicates that aging results in 
osmoreceptor hypersensitivity [35]. The ability of intravenous ethanol 
infusion to suppress the arginine vasopressin secretion has been evaluated 
in younger and elderly normal persons. Young persons showed a 
persistent suppression of arginine vasopressin release. But the geriatric 
population showed an arginine vasopressin suppression at the start of 
infusion but later showed an elevation in arginine vasopressin to two 
times that of the baseline. This results shows ethanol is not potent in 
suppression of arginine vasopressin secretion in geriatric age group and 
also lost the inhibitory action completely due to ethanol favoured 
constriction of blood volume [35]. This studies shows, arginine 
vasopressin responses to osmotic stimulus is high due to osmoreceptor 
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hypersensitivity. Arginine vasopressin secretion to erect posture is 
decreased due to impairment in baroreceptor function.signals from the 
baroreceptor to the osmoreceptor is suppressive. A defect in this would 
lead to an inappropriate production of arginine vasopressin. This defects 
along with changes in kidney function due to aging, places the geriatric 
persons at risk of hyponatremia. 
 
INTEGRATION OF ARGININE VASOPRESSIN SECRETION 
AND THIRST: 
In normal physiologic circumstances, the sensitivity of the 
osmoregulatory system for AVP secretion is responsible for maintenance 
of plasma osmolality within narrow limits by adjusting amount of water 
excreted through the kidneys following small changes in osmolality. 
Stimulated thirst does not represent a major regulatory mechanism under 
these conditions, and an unregulated fluid ingestion supplies water in 
excess of true need. This is then excreted in relation to osmoregulated 
pituitary arginine vasopressin secretion. However, when unregulated 
water intake is not enough to supply body needs in the presence of 
plasma arginine vasopressin levels sufficient to produce maximal 
antidiuresis, then serum osmolality rises to levels that trigger thirst 
leading to water intake in proportion to the increase in osmolality above 
this thirst threshold. Thirst essentially represents a back-up mechanism 
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that comes into play when pituitary and renal mechanisms prove 
inadequate to maintain plasma osmolality within a few percent of basal 
levels. Stimulation of arginine vasopressin secretion at serum osmolalities 
below the threshold for subjective thirst acts to maintain an excess of 
body water adequate to eliminate the need to consume water whenever 
minimal elevations in serum osmolality occur. This system of different 
effective thresholds for thirst and arginine vasopressin secretion 
complements many studies that have demonstrated excess unregulated 
drinking in both humans and other animals. Only when this mechanism 
becomes insufficient to maintain body fluid homeostasis, thirst-induced 
regulated fluid intake becomes the predominant mechanism to prevent 
severe dehydration. 
 
THE KIDNEY AND WATER BALANCE: 
Regulation of water balance largely depends on the kidney's ability 
to excrete urine with an osmolality that varies from a minimum value of 
50 mosm/kg water to a maximum of 900 to 1400 mosm/kg water. This 
wide range of urine osmolality indicates the changes in collecting duct 
water permeability depending on the absence of AVP (low urine 
osmolality, production of dilute urine, water diuresis) or the presence of 
AVP (high urine osmolality, production of concentrated urine, 
antidiuresis). 
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The kidney’s ability to produce maximal urine dilution in states of 
water excess depends on 3 important steps: 
1. Adequate delivery of filtrate to the collecting tubule thereby 
ensuring sufficiently high flow rates that prevent the equilibration 
of urine in the collecting duct with the hypertonic renal 
interstitium. Adequate distal delivery requires a normal GFR and 
normal reabsorption in the proximal segment.  
2. Active transport of sodium chloride without water in the thick 
ascending limb of the loop of Henle.  This decreases the 
osmolality of fluid reaching the distal tubule to 50 to 100 mosm 
/kg of water. 
3. Absence of vasopressin. This maintains the intrinsic property of 
low water permeability of the collecting duct. 
The capacity of the kidney to produce maximum urine 
concentration and reduce water loss to a minimum in a water depleted 
state requires the following important steps:  
1. Active transport of NaCl without water in the thick ascending limb 
of the loop of Henle. This produces dilution of the fluid in the 
tubular lumen and concentration in the renal interstitium. 
2. Enhancement of the effect of above said step by the entry of NaCl 
into the descending limb of the loop of Henle and the efflux of 
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water from this segment (through water permeable channels known 
as aquaporin-1) thereby progressively increasing the osmolality 
both of the fluid in the lumen of the descending limb of the loop of 
Henle and the renal interstitium from the corticomedullary junction 
to the inner medulla. This process is known as countercurrent 
multiplication.[36]. 
3. Maintenance of the corticomedullary osmotic gradient by the vasa 
recta that reach osmotic equilibrium with the interstitium, as they 
allow solutes and water to pass through and remove fluid from the 
renal interstitium (ascending vasa recta blood flow is almost double 
that of descending vasa recta) [37].This process is known as 
countercurrent exchange. 
4. Preservation of a relatively low blood flow in the renal medulla and 
papilla that prevents the removal of solutes (largely NaCl and urea) 
from the renal interstitium and 
5. Presence of vasopressin to ensure water reabsorption from the 
collecting duct. 
EFFECT OF AGING IN KIDNEY: 
CHANGES IN STRUCTURE AND FUNCTION: 
Aging is accompanied by changes in the anatomy and function of 
the kidney. The total glomeruli number in nephron decreases by 30% to 
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40% with increasing age and the percentage of hyalinized or sclerotic 
glomeruli increase by 10% to 30%. This phenomenon accelerates after 40 
years of age, causing the residual glomeruli also to undergo changes. 
Thus, there is a decrease in effective filtering surface and no of epithelial 
cells, with an increase in the number of mesangial cells and thickening of 
the glomerular basement membrane. Normal aging process also produces 
changes in the renal vasculature that leads to obliteration of the arteriolar 
lumen and loss of the glomerular capillary tuft which take place primarily 
in the cortical glomeruli. Renal blood flow declines with age at the rate of 
around 10% with every decade after young adulthood so that by 90 years 
of age the renal plasma flow is approximately 300 ml/min—a value that 
is only 50% of the RPF found at 30 years of age. Glomerular filtration 
rate (GFR) remains relatively constant until age of 40 years, after which it 
declines at an annual rate of approximately 0.8 mL/min/1.73 m2. 
CHANGES IN WATER REGULATION: 
RENAL WATER RETENTION: 
The aging kidney exhibits impairment in the ability to dilute the 
urine and excrete a water load. The most important factor for decline in 
diluting capacity of aging kidney is the age related decrease in RPF and 
GFR. In addition to impaired diluting capacity, the decrease in renal 
plasma flow and GFR favours the passive reabsorption of fluid which 
increases the risk of fluid overload and hyponatremia. This effect is 
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clinically evident in elderly patients who have congestive heart failure, 
extracellular volume depletion and hypoalbuminemia. Diuretics, ( 
thiazides especially) can reduce the diluting capacity of the kidney. In the 
elderly, this effect becomes significant when it is superimposed on the 
already diminished diluting capacity of the kidney, thereby increasing the 
risk of developing water intoxication by impairing the ability to excrete 
excess water. 
RENAL WATER LOSS: 
It is known that there is an age associated decline in renal 
concentrating ability. An age-related increase in vasopressin secretion 
may result in down-regulation of AVP receptors in the kidney which 
maybe the basis for decreased renal concentrating capacity in the elderly. 
 
SODIUM REGULATORY CAPACITY: 
RENAL SODIUM RETENTION: 
A number of factors and circumstances may lead to Na retention. 
There is increased sodium conservation owing to age related decrease in 
renal blood flow and GFR. Conditions like congestive heart failure, 
cirrhosis, nephrotic syndrome that lead to secondary hyperaldosteronism 
is common in elderly. Drugs like NSAIDS used commonly in elderly may 
augment sodium retention.. 
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RENAL SODIUM LOSS: 
When compared with young individuals elderly individuals have 
an exaggerated sodium loss in urine after a water load. Benign 
hypertension patients have excess sodium excretion with increasing age. 
Mechanisms underlying this tendency maybe due to a number of factors 
and are related to the effects of senility of atrial natriuretic hormone, the 
RAAS and renal tubular function. 
 
AGE RELATED CHANGES IN SECRETION, REGULATION 
AND ACTION OF ATRIAL NATRIURETIC HORMONE: 
Atrial natriuretic hormone is produced, stored and secreted in atria 
of the heart. It produces natriuresis & dieuresis by its effect on kidney. It 
acts on the blood vessels producing vasodilation thereby decreasing the 
blood pressure. It may be an important factor associated with altered renal 
sodium handling due to aging. In a comparison of normal young men 
with elderly men in nursing homes, a fivefold increase in mean basal 
ANH levels with an exaggerated ANH was noted in the elderly in 
response to saline infusion. In response to the stimulus of head-out water 
immersion, ANH levels of healthy older individuals (age 62–73 years), 
which were twice as high at baseline as in young subjects (age 21–28 
years), rose to a greater extent than in the young [38]. Thus increase in 
age results in increase in basal levels of ANH and an increase in response 
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to both physiologic and pharmacologic stimuli. This may be the 
consequence of age related decrease in cardiac muscle compliance. 
Studies suggest that the action of ANH on the kidney may be higher in 
geriatric age group than in young persons. It is known that ANH can 
interact with RAAS. Increase in ANH results in downregulation of renin 
release, plasma renin function, angiotensin II and aldosterone levels, 
suggesting an indirect negative regulation of aldosterone secretion by 
atrial natriuretic hormone. Thus, atrial natriuretic hormone may cause 
urinary Na+ excretion in 2ways by inhibiting aldosterone secretion and 
by direct natriuretic action. Atrial natriuretic hormone may be a 
significant cause of age related urinary Na+ excretion. This phenomenon 
may be the result of rise in baseline atrial natriuretic hormone levels, 
augmented ANH reaction to stimuli, increase in the response of the 
kidney to atrial natriuretic hormone, and atrial natriuretic peptide induced 
downregulation of adrenal sodium-retaining hormones. 
 
 
CHANGES IN RAAS WITH AGE:  
Studies suggest that aging affects the RAAS. Normal elderly (age 
61–70 years) with normal dietary sodium intake have lower serum renin 
function and aldosterone levels while in the supine posture than normal 
young adults (age 21–30 years). On changing to upright posture and 
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during Na+ depletion, prominent rise in levels of renin and aldosterone 
occurred in the young and elderly, but average values reached were 
always lower in the older age group [39]. The fall in serum renin function 
in the older population is not due to changes in serum renin substrate 
levels but due to fall in active renin levels. It may be caused by reduced 
activation of renin. The reduction in serum renin activity may also be due 
to inhibition by elevated levels of atrial natriuretic hormone on renin 
release. Fall in aldosterone levels with age seems to be due to reduction in 
serum renin function due to age and not to age related changes in the 
adrenals. It is probable that the reduction in aldosterone levels leads to 
urinary salt loss in the geriatric age group. Alterations in intrinsic tubular 
function may also play a role in salt loss. Faulty sodium reabsorption has 
been noted along with reduced response of renal tubule to aldosterone 
administration. The reduction in activity of the RAAS may be the result 
of changes in K+ regulation. Hyporeninemic hypoaldosteronism occurs 
most frequently in geriatric individuals, particularly diabetics. The 
hyperkalemia which is a feature of the disorder gets corrected on 
mineralocorticoid administration and maybe the effect of interplay 
between chronic renal disease & the hormonal changes of aging. The risk 
of ACE  inhibitors leading to hyperkalemia is particularly high in older 
people, and may also be a result of  interaction between effect of the drug 
and physiologic alteration caused by aging. 
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ETIOLOGY OF HYPONATREMIA: 
The plasma Na+ sodium level is determined by the body's content 
of sodium, potassium, and TBW. Thus: 
Serum sodium: Total body Na
+
 + total body K
+
 / total body water. 
Hyponatremia can therefore occur by an increase in TBW, a decrease in 
body solutes (either Na
+
 or K
+
), or any combination of these. But in most 
cases more than one mechanism is responsible for hyponatremia. In 
approaching the hyponatremic patient, it is very important to ensure that 
hyponatremia reflects a hypo-osmotic state and is not a consequence of 
the causes of pseudohyponatremia. Assessment of ECF volume provides 
a useful working classification of hyponatremia as it can be associated 
with decreased, normal, or high total body sodium: 
(1) Hyponatremia with ECF volume depletion,  
(2) Hyponatremia with excess ECF volume, and  
(3) Hyponatremia with normal ECF volume [40]. 
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HYPONATREMIA WITH EXTRACELLULAR FLUID VOLUME 
DEPLETION: 
Patients with hyponatremia who have ECF volume depletion have 
reduced total body Na+ and TBW. But the deficit in total body Na+ is in 
excess of deficit in total body water. Volume depletion can be associated 
with normal supine BP but fall of the systolic level greater than 15 mm 
Hg on standing. Also, a rise in heart rate of more than 15beats/min on 
standing from supine posture and reduced JVP can be noted. A severe 
volume loss can lead to fall in BP in lying posture also, fall in tissue 
plasma flow, and reduced skin turgor. Ocular pressure falls and mucous 
membranes become dry. Signs of intracellular volume loss come to play 
only when the volume depletion is quite acute or severe, as retention of 
H2O can compensate the severity of the fluid depletion. A rise in serum 
creatinine and a proportionately greater rise in BUN concentration are 
characteristically seen indicating the associated fall in glomerular 
filtration rate and accentuated urea reabsorption by the kidney If 
sufficiently severe, volume depletion is a potent stimulus to AVP release. 
When the osmoreceptor and volume receptor receive opposing stimuli, 
the former remains fully active but the set-point of the system is lowered. 
Thus, in the presence of hypovolemia, AVP is secreted and water is 
retained despite hypo-osmolality. Whereas the hyponatremia in this 
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setting clearly involves a depletion of body solutes, a concomitant failure 
to excrete water is critical to the process. In hypovolemic hyponatremia 
the source of fluid loss is whether renal or extrarenal in origin is assessed 
by examining the urinary sodium concentration. 
EXTRARENAL LOSS: 
A urinary sodium concentration of ≤ 20 mEq/L reflects an 
adequate response of kidney to volume loss and indicates another source 
of fluid loss apart from the kidneys. This is most commonly seen in 
patients with gastrointestinal disease with vomiting or diarrhea. Other 
causes of extrarenal loss include loss of fluid into the third space, such as 
the abdominal cavity in pancreatitis or the bowel lumen with ileus. Burns 
and muscle trauma can also leads to large fluid and electrolyte losses. 
Because many of these pathologic states are associated with thirst, an 
increase in either orally or parenterally taken free water leads to 
hyponatremia.  
RENAL LOSS: 
Hypovolemic hyponatremia in patients with urinary Na
+
 
concentration is ≥ 20 mEq/L renal loss of fluid volume.  
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DIURETICS: 
Diuretic-induced hyponatremia accounts for a significant 
proportion of symptomatic hyponatremia in hospitalized patients. It 
occurs almost exclusively with thiazide rather than loop diuretics, most 
likely because the former have no action on urine concentrating function 
in contrast to the latter. The hyponatremia is normally seen within 14 
days but can occur up to 2 years in most patients [41]. Underweight 
women appear to be particularly prone to this complication [42] and 
advanced age has been found to be a risk factor in some patients. Studies 
on diluting capacity of geriatric patients shows that thiazide diuretics 
aggravate the already slower recovery from hyponatremia induced by 
water ingestion in this population [43].  
Diuretics can cause hyponatremia by a variety of mechanisms:  
(1) Volume depletion, which results in impaired water excretion by both 
enhanced AVP release and decreased volume delivery to the diluting 
segment;  
(2) Direct effect of diuretics on the diluting segment; and  
(3) K
+
 depletion causing a decrease in the water permeability of the 
collecting duct as well as an increase in water intake 
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 K
+
 depletion leads to hyponatremia independent of the Na
+
 depletion that 
frequently accompanies diuretic use [43]. The concomitant administration 
of K
+
-sparing diuretics does not prevent the development of 
hyponatremia. Diagnosis of diuretic induced hyponatremia is suspected 
when there is other electrolyte abnormalities as well as high urinary 
chloride clearance. 
SALT LOSING NEPHROPATHY: 
In advanced renal insufficiency some patients may have salt losing 
nephropathy. Salt-wasting nephropathy refers to a state of volume loss 
and associated fall of serum Na
+ 
 levels observed in patients with 
advanced CRF (GFR  less than15 millilitres/minute) consuming diet with 
low Na
+
 content. In the majority of these patients, the Na
+
-wasting 
tendency is not one that manifests itself at normal rates of sodium intake; 
however, some patients with interstitial nephritis, MCD, ADPKD with 
sufficient Na+ wasting exhibit hypovolemic hyponatremia [44].  
BICARBONATURIA: 
Sodium and water excretion are also increased when a non 
reabsorbable anion appears in the urine .Patients with proximal renal 
tubular acidosis exhibit renal sodium and potassium wasting despite 
modest renal insufficiency because bicarbonaturia present in the renal 
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tubular acidosis obligates these cation losses. The metabolic alkalosis and 
bicarbonaturia that accompany severe vomiting or nasogastric suction is 
also associated with sodium loss. In these patients, for the maintenance of 
electroneutrality, the excretion of HCO3
- requires the excretion of cations, 
including sodium and potassium. Whereas the renal losses in these 
clinical settings may be hypotonic, the volume contraction-stimulated 
thirst and water intake can result in the development of hyponatremia. 
 
MINERALOCORTICOID DEFICIENCY: 
It has been recognized that adrenal insufficiency is associated with 
impaired renal water excretion and hyponatremia. This diagnosis of 
adrenal insufficiency should be considered in the volume-contracted 
hyponatremic patients whose urinary Na
+
 concentration is high, 
particularly when the serum K+, BUN, and creatinine levels are elevated. 
The mechanism of the defect in water excretion associated with 
mineralocorticoid deficiency is mediated by AVP and by AVP-
independent intrarenal factors, both of which are activated by depletion of 
ECF volume. 
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KETONURIA:  
The presence in the urine of an osmotically active nonreabsorbable 
solute causes renal excretion of sodium and culminates in volume 
depletion. Glycosuria secondary to uncontrolled diabetes mellitus, 
mannitol infusion, or urea diuresis after relief of obstruction is a common 
setting for this disorder. In patients with diabetes, the Na
+
 wasting caused 
by the glycosuria can be aggravated by ketonuria because 
hydroxybutyrate and acetoacetate also cause urinary electrolyte losses. 
Ketonuria can contribute to the renal sodium wasting and hyponatremia 
seen in starvation and alcoholic ketoacidosis. 
 
CEREBRAL SALT WASTING SYNDROME: 
Cerebral salt wasting is manifested by hyponatraemia, urinary loss 
of NaCl, and fluid loss in persons having neurological disorders [45]. 
This syndrome of unclear pathogenesis is seen frequently in head injury 
patients with SAH. It normally gets corrected in a couple of weeks. The 
mechanism of urinary sodium excretion has been ascribed to a BNP or 
reduced sympathetic activity. 
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HYPONATREMIA WITH EXCESS EXTRACELLULAR FLUID 
VOLUME: 
Patients with hypervolemic hyponatremia show an increase in 
plasma Na+  followed by a proportionately larger increase in TBW, 
resulting in a decreased serum Na+ levels. In hypervolemic hyponatremia 
the source of fluid loss is whether renal or extrarenal in origin is assessed 
by examining the urinary sodium concentration. Arterial filling and 
circulatory integrity is decreased in CCF, chronic liver disease, and 
nephrotic syndrome. This can lead to fall in serum sodium levels because 
of increased AVP release [46]. This effect is directed via carotid 
baroreceptors that sense a fall in arterial stretch and override the 
suppressive action of hypotonicity on arginine vasopressin secretion. In 
conditions other than kidney failure, these conditions show prominent 
sodium retention (urinary sodium levels less than 10 mEq/Litre). This 
retention may be hidden by the concurrent usage of diuretics, which are 
frequently used in treating these patients. These agents can further 
contribute to the abnormal water excretion seen in these states. The 
degree of hyponatremia provides an indirect index of the associated 
neurohumoral activation and is an important prognostic indicator in 
hypervolemic hyponatremia. 
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EXTRA RENAL CAUSES: 
A urinary sodium concentration of less than 20 mEq/L points to a 
extra renal cause of hypervolemic hyponatremia. 
CONGESTIVE CARDIAC FAILURE:  
Reduced perfusion caused by decrease in ejection fraction in 
patients with CCF leads to stimulation  of RAAS, ADH, noradrenaline 
that leads to faulty H2O excretion by the kidneys and causes hypotonic 
hyponatremia. Hyponatremia is common in patients with severe CCF in 
whom a plasma sodium ≤ 130 mEq/Litre indicates a reduced life 
expectancy unless heart function improves [47]. A combination to H2O 
restriction, an ACE inhibitor, and a loop diuretic helps to normalize the 
hyponatremia [48]. 
CIRRHOSIS: 
There is no disturbance in kidney water handling in the earlier 
course of the disease before the onset of ascites. Persons having end stage 
liver disease frequently manifest hyponatremia due to their inability to 
excrete a water load [49].With the progression of liver disease the 
secretion of AVP increases. This predisposes the patient with cirrhosis to 
hyponatremia [50]. In advanced cirrhosis due to marked dilation of blood 
vessels in splanchnic circulation and stimulation of the RAAS and 
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adrenergic nerves, there is reduction in renal blood flow. This also 
appears to contribute to a smaller extent to faulty urinary H2O loss. The 
chances of manifesting hyponatremia is more in patients with cirrhosis 
who are alcoholic (beer potomania) or in persons having fluid loss as a 
result of diuretic use or ascitic fluid tap without edema. A plasma sodium 
≤ 130 mEq/litre has bad outcome and levels <125 mEq/litre are seen in 
advanced cirrhosis. Commonly cirrhotics have asymptomatic 
hyponatremia though it may aggravate hepatic encephalopathy [51]. 
NEPHROTIC SYNDROME: 
Faulty urinary water loss and mild hyponatremia is seen in persons 
having nephrotic syndrome .The prevalence of hyponatremia in the 
nephrotic syndrome is lesser than CCF or cirrhosis. It is most likely due 
to the higher blood pressure, higher GFR, and more modest impairment 
in Na+ and water excretion in nephrotic syndrome than in congestive 
heart failure or cirrhosis [52]. The pathogenesis may vary in patients with 
normal kidney function like minimal change disease than in persons 
having reduced GFR. ADH secretion stimulated by a reduction in blood 
volume seems to be impaired in persons with nephrotic syndrome, 
albumin deficiency & normal kidney function. In contrast, hypervolemia 
may be more prevalent in patients with underlying glomerular pathology 
and reduced renal function. Rigorous diuretic usage may lead to severe 
sodium loss in nephrotics.  
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RENAL FAILURE: 
Hyponatremia can occur with end stage kidney failure. In such 
people with renal failure the excretion of free water is limited by a 
decrease in GFR. In later stages of impairment in renal function, the urine 
osmolality ranges from 200 to 250 milliosmoles/kilogram of water inspite 
of appropriate downregulation of AVP release. Thus unlimited fluid 
consumption may cause hyponatraemia. A decrease in GFR with an 
increase in thirst underlies the hyponatremia of patients with renal 
insufficiency. The higher level of urine osmolality is a result of increase 
in loss of solutes per nephron causing osmotic diuresis. Persons having 
ESRD, on hemodialysis experience significant collection of extracellular 
fluid during interdialysis times, but the fall in Na
+
 is rarely severe which 
is because the water intake is an effect of hypertonicity due to salt 
ingestion. 
HYPONATREMIA WITH NORMAL ECF VOLUME: 
HYPOTHYROIDISM: 
Patients with severe hypothyroidism may have hyponatremia with 
normal ECF volume. There may be decrease in GFR and decrease in 
renal plasma flow in patients with hypothyroidism. There is an alteration 
in the osmotic threshold of arginine vasopressin secretion. Patients with 
severe hypothyroidism have higher levels of AVP. There is also a 
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decrease in glomerular filterate delivery to the diluting segment of 
kidney. Thus both these mechanism operate in patients with 
hypothyroidism and contributes to hyponatremia by impaired water 
excretion. 
GLUCOCORTICOID DEFICIENCY: 
Glucocorticoids may exert direct inhibitory action on AVP 
secretion. So its deficiency increases vasopressin secretion in patients 
with primary adrenal insufficiency [53]. Prolonged glucocorticoid 
deficiency is associated with decrease in renal hemodynamics that 
impairs water excretion. Elevated serum K
+
 is specifically not seen in 
isolated glucocorticoid deficiency but frequently found in other forms of 
adrenal deficiency. It is an important clue in differentiating different 
forms adrenal insufficiency. 
 
SYNDROME OF INAPPROPRIATE ANTI DIURETIC 
HORMONE SECRETION: 
In these patients, the AVP secretion is not controlled by 
hemodynamic or osmotic stimulus. This leads to water retention. Control 
of sodium balance remains stable in patients with SIADH. Urinary 
sodium concentration reflects sodium intake in these patients. Urinary 
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Na
+
 concentration is usually high, but it is low in SIADH patients with 
low sodium diet. Thus the ECF volume appears normal and patients are 
without signs of hypervolemia. The diagnosis of SIADH depends on  
1. The detection of hypoosmolar hyponatremia , 
2.  Inappropriate urine concentration ( osmolality more than 100 
milliOsmoles/kg of water), 
3.  Euvolaemia that is clinically evident, 
4.  High urine Na+ levels with normal sodium consumption,  
5. Normal  GFR and  
6. Absence of diuretic use, glucocorticoid insufficiency, or 
hypothyroidism 
Accurate diagnosis of SIADH may need measurement of plasma 
ADH, and the effect of a water load test in some patients. Results 
indicative of diagnosis of SIADH are: 
1. increased AVP despite low plasma osmolality, 
2.  failure to lower urine osmolality < 100 milliosmoles/kg water in 
response to a water load  
3.  Inability to excrete at least eighty per cent of the load within 4 
hours, and  
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4. Inability to normalize the low sodium values with volume 
expansion but improvement after water restriction. 
CAUSES OF SIADH: 
There are many causes of SIADH including  
• Tumors of the lung , gastrointestinal tract, urological 
malignancies, sarcomas,  
• Various acute or chronic infections of the respiratory system, 
•  Various central nervous system disorders including 
infections, delirium, multiple sclerosis, shy dragger 
syndrome, acute intermittent porphyria, and cerebrovascular 
accidents including intracerebral bleed. 
• There are number of drugs causing SIADH some of which 
are fluoxetine , carbamazepine, nicotine, oxytocin, tricyclic 
antidepressants, desmopressin, vasopressin analogues, 
vincristine and antipsychotic drugs. 
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OTHER CAUSES OF HYPONATREMIA 
Postoperative hyponatremia: 
            Postoperative hyponatremia develops due to persistent 
vasopressin secretion in patients treated with large amounts of 
electrolyte-free water. Associated stressors like pain,nausea and drugs 
trigger vasopressin release. However many patients are euvolaemic and 
asymptomatic. 
Hyponatraemia caused by decreased excretion of solutes 
       Low solute excretion decreases the maximal urine volume and causes 
dilutional hyponatraemia if associated with a high water intake. Examples 
are the tea-and-toast diet, in aged individuals of poor means, and beer 
potomania where there is decreased solute excretion. 
Primary polydipsia 
       Primary polydipsia is seen in psychotics mainly schizophrenics, and 
in anxious, middle-aged females. These people drink a large amount of 
water that is compounded by a diminished capacity of renal water 
excretion. Contributing factors include a central defect in thirst regulation 
, an excessive ADH secretion and consequences of drug therapy. 
Primary polydipsia also occurs in lesions affecting hypothalamic thirst 
centre as in sarcoidosis, multiple sclerosis and tuberculous meningitis. 
The recreational drugs like amphetamine and ecstasy cause 
hyponatraemia by increasing water intake and ADH release. 
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Hyponatremia associated with sodium-free irrigant solutions 
      Sodium-free flushing solutions with glycine, sorbitol, or mannitol are 
used in TURP and gynaecological surgeries. The solutions have low 
osmolality that decrease serum sodium. These organic solutes undergo 
metabolic degradation leaving behind the free water of the irrigant 
solution. The diagnosis is made from the clinical history and by the 
demonstration of a high osmolal gap. 
 
Other causes of hyponatremia due to excessive water intake 
        Multiple tap water enemas in thin subjects  
        Accidental intake of large amounts of water during swimming 
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MATERIALS AND METHODS 
STUDY CENTRE: 
RG GGH AND MMC, Chennai 
ETHICAL COMMITTEE APPROVAL: 
Ethical committee clearance obtained from Institutional Ethical 
Committee of MADRAS MEDICAL COLLEGE held on 19.06.2012  
STUDY DESIGN: 
Hospital based observational study. 
PERIOD OF STUDY: 
6 months, from June 2012 to December 2012 
STUDY POPULATION: 
Hundred patients. 
INCLUSION CRITERIA: 
1. Elderly patients 65 years and above. 
2. Patients with serum sodium levels less than 135 mEq/litre. 
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EXCLUSION CRITERIA: 
1. Patients with age less than 65 years. 
2. Pseudohyponatremia. 
DETAILS OF THE STUDY: 
100 patients admitted in RGGG Hospital having serum sodium level less 
than 135 mEq/litre are included in the study with proper informed 
consent in their regional language. Detailed history and clinical 
examination were performed in patients diagnosed to have hyponatremia. 
Blood and urine samples were taken from patients for relevant 
investigations with proper consent. 
SERUM SODIUM: 
Sodium is the principal cation in extracellular fluid. It is essential for the 
proper control of blood volume, blood pressure, osmotic equilibrium and 
pH. It is measured by taking 5 ml of venous blood. Serum sodium level is 
estimated using ion specific electrode in the automated analyzer which 
performs various analysis within a single machine. 
PLASMA OSMOLALITY: 
Plasma osmolality is defined as the measure of concentration of solutes in 
one kilogram of water. It is expressed in milliosmoles/ kg of water. 
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 It can be estimated by the following formula: 
Plasma osmolality = 2x serum [Na
+
] + glucose/18+BUN/2.8 
• Serum sodium in milliequivalents/litre 
• Random blood glucose in milligrams/decilitre 
• BLOOD UREA NITROGEN in milligrams/decilitre 
Normal serum osmolality is 275 to 290 mOsm/kg of water. 
ASSESSMENT OF VOLUME STATUS: 
By the assessment of volume status patients with hyponatremia were 
categorized into euvolemic, hypovolemic and hypervolemic. It is assessed 
clinically by examining for 
• Pulse 
• Blood pressure 
• Examining mucus membranes 
• Urine output 
• Jugular venous pressure 
• Hepatojugular reflex 
• Presence or absence of cold and clammy extremities 
• Peripheral edema 
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• Ascites 
• Pulmonary congestion 
• Capillary refill. 
URINARY SODIUM ESTIMATION: 
Patients after the assessment of volume status is estimated for the urinary 
sodium excretion by urine spot sodium examination test. When urinary 
sodium excretion is more than 20 it points to sodium loss attributable to 
a renal cause and when it is less than 20 it points to extrarenal source of 
sodium loss. 
THYROID FUNCTION TEST: 
This test is performed in selected patients to rule out hypothyroidism in 
euvolemic hyponatremia. Estimation of TSH is the most sensitive test to 
detect hypothyroidism. The normal range of the TSH in our laboratory is 
between 0.3 to 5.0 mIU/litre. 
COSYNTROPIN TEST: 
It is done in selected patients with euvolemic hyponatremia. It is a 
stimulation test performed to rule out the adrenal insufficiency. In this 
test 250 microgram of synthetic ACTH co syntropin is injected 
intravenously or intramuscularly whichever is feasible. Basal levels of 
ACTH and cortisol are measured before injection. Patient should be 
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prepared by overnight fasting. Venous blood is collected at thirty 
minutes and sixty minutes after the injection and the values are 
interpreted to rule out adrenal insufficiency. 
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OBSERVATION AND RESULTS 
 
TABLE 1: AGE DISTRIBUTION 
AGE NO OF PATIENTS PERCENTAGE 
65-75 72 72 
76-85 23 23 
86-95 5 5 
 
 
FIGURE 1 AGE DISTRIBUTION 
AGE DISTRIBUTION: 
Out of hundred patients studied, 72 patients (72 percent) fall 
within the age group of 65 to 75 years, 23 patients fall within 
the age group of 76 to 85 years (23 percent), and 5 patients fall 
within the age group of 86 to 95 years. 
72%
23%
5%
AGE DISTRIBUTION
65-75 76-85 86-95
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TABLE 2: SEX DISTRIBUTION 
SEX NO.OF PATIENTS PERCENTAGE 
MALE 57 57 
FEMALE 43 43 
 
 
 
 
 
FIGURE 2 SEX DISTRIBUTION 
 
SEX DISTRIBUTION: 
Out of 100 patients studied, 57 were male patients (57 percent) 
and 43 were female patients (43 percent). 
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TABLE 3: SEX DISTRIBUTION IN DIFFERENT AGE GROUP 
AGE NO.OF 
PATIENTS 
MALE PERCENTAGE 
OF MALE 
FEMALE PERCENTAGE 
OF FEMALE 
65-
75 
72 42 73.68 30 69.76 
76-
85 
23 11 19.29 12 27.9 
86-
95 
5 4 7.01 1 2.32 
Out of 72 patients in the age group of 65 to 75, 42 patients were male 
(73.68 percent), 30 patients were female (69.76 percent).In the age 
group of 76 to 85 years, out of 23 patients, 11 were male patients 
(19.29 percent), 12 were female patients (27.9 percent).Out of 5 
patients in the age group 0f 86 to 95, 4 patients were male (7.01 
percent) and 1 patient was female (2.32 percent). 
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TABLE 4: COMORBID ILLNESS IN HYPONATREMICS 
 
COMORBIDITY NO.OF PATIENTS 
HYPERTENSION 52 
DIABETES MELLITUS 28 
CAD 18 
TB 3 
HYPOTHYROIDISM 4 
CKD 11 
 
 
FIGURE 4 COMORBID ILLNESSES IN HYPONATREMICS 
COMORBID ILLNESS IN HYPONATREMIC PATIENTS: 
Out of 100 patients, 52 patients had hypertension, 28 patients 
had Diabetes mellitus, 18 patients had CAD, 3 patients had TB, 
4 patients had hypothyroidism, and 11 patients had CKD.  
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TABLE 5: COMORBID ILLNESS IN MALES 
COMORBIDITY  NO.OF PATIENTS 
HYPERTENSION 32 
DIABETES MELLITUS 15 
CAD 12 
TB 2 
CKD 5 
 
COMORBID ILLNESS IN MALES: 
Out of 57 male patients, 32 had hypertension, 15 had diabetes 
mellitus, 12 had CAD, 2 had TB and 5 had CKD.  
 
 
 
Figure 5: Comorbid illness in males 
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TABLE 6: COMORBID ILLNESS IN FEMALES 
COMORBIDITY NO OF PATIENTS 
Hypertension 20 
Diabetes 13 
CAD 6 
TB 1 
Hypothyroidism 4 
CKD 6 
 
COMORBID ILLNESS IN FEMALES: 
Out of 43 female patients, 20 had hypertension, 13 had diabetes 
mellitus, 6 had CAD, 1 had TB, 4 had hypothyroidism, 6 had 
CKD. 
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TABLE7: SYMPTOMS IN HYPONATREMIC PATIENTS 
SYMPTOMS NO OF PATIENTS 
Malaise 92 
Nausea 52 
Altered sensorium 51 
Headache 28 
Vomiting 26 
Diarrhea 7 
Seizures 9 
Coma 6 
Cramps 9 
SYMPTOMS IN HYPONATREMIC PATIENS: 
Out of 100 patients, 28 patients had headache, 52 patients had 
nausea, 26 had vomiting, 7 had diarrhea, 92 had malaise, 51 had 
altered sensorium, 9 had seizures, 6 had coma and 9 had 
cramps. 
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TABLE 8: SYMPTOMS IN MALES 
SYMPTOMS NO OF PATIENTS 
Malaise 55 
Nausea 33 
Altered sensorium 33 
Headache 18 
Vomiting 17 
Seizures 4 
Coma 4 
Cramps 3 
Diarrhea 2 
Out of 57 patients, 18 had headache, 33 had nausea, 17 had vomiting, 
2 had diarrhea, 55 had malaise, 33 had altered sensorium, 4 had 
seizures, 4 had coma and 3 had cramps. 
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TABLE 9: SYMPTOMS IN FEMALES 
SYMPTOMS NO OF PATIENTS 
Headache 10 
Nausea 19 
Vomiting 9 
Diarrhea 5 
Malaise 37 
Altered sensorium 18 
Seizures 5 
Coma 2 
Cramps 6 
Out of 43 female patients, 10 had headache, 19 had nausea, 9 had 
vomiting, 5 had diarrhea, 37 had malaise, 18 had altered sensorium,5 
had seizures , 2 had coma and 6 had cramps 
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TABLE 10: SEVERITY OF HYPONATREMIA 
SERUM SODIUM(in mEq/l) NO OF PATIENTS 
105-115 7 
116-125 33 
126-134 60 
 
SEVERITY OF HYPONATREMIA: 
Out of 100 patients, 60 had serum sodium levels between 126-
134 mEq/litre, 33 had serum sodium levels between 116-125 
mEq/litre, 7 had serum sodium levels in between 105-115 
mEq/litre. 
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TABLE 11: SEVERITY IN MALES 
SERUM SODIUM(in mEq/l) NO OF PATIENTS 
105-115 3 
116-125 22 
126-134 32 
 
SEVERITY IN MALES: 
Out of 57 male patients,32 patients had serum sodium level 
between 126-134 mEq/litre, 22 patients had serum sodium 
levels between 116-125 mEq/litre and 3 patients fall in between 
serum sodium levels of 105 -115 mEq/litre. 
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TABLE 12: SEVERITY IN FEMALES 
SERUM SODIUM(In mEq/l) NO OF PATIENTS 
105-115 4 
116-125 11 
126-134 28 
SEVERITY IN FEMALES: 
Out of 43 female patients, 28 patients had serum sodium levels 
between 126-134 mEq/litre, 11 patients had serum sodium 
levels between 116-125 mEq/litre and 4 patients fall between 
serum sodium levels of 105-115 mEq/litre. 
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TABLE 13: HYDRATION STATUS 
HYDRATION STATUS NO OF PATIENTS 
EUVOLEMIC 42 
VOLUME OVER LOAD 31 
HYPOVOLEMIA 27 
 
HYDRATION STATUS: 
Out of 100 patients, 42 patients showed normal hydration status, 
31 patients were in volume overload status and 27 patients were 
dehydrated. ( table 13 and figure 13). 
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TABLE 14: TYPES OF HYPONATREMIA 
 
TYPES OF HYPONATREMIA 
Out of 100 patients, 42 patients had hypoosmolar euvolemic 
hyponatremia, 31 patients had hypoosmolar hypervolemic 
hyponatremia and 27 patients had hypoosmolar hypovolemic 
hyponatremia. 
FIG 14: TYPES OF HYPONATREMIA 
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TABLE 15: TYPES OF HYPONATREMIA IN MALES 
 
TYPES OF HYPONATREMIA IN MALES: 
Out of 57 patients, 25 patients had hypoosmolar euvolemic 
hyponatremia, 18 patients had hypoosmolar hypervolemic 
hyponatremia and 14 patients had hypoosmolar hypovolemic 
hyponatremia.  
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TABLE 16: TYPES OF HYPONATREMIA IN FEMALES 
 
TYPES OF HYPONATREMIA IN FEMALES: 
Out of 43 patients, 17 patients had hypoosmolar euvolemic 
hyponatremia, 13 patients had hypoosmolar hypervolemic 
hyponatremia and 13 patients had hypoosmolar hypovolemic 
hyponatremia. (Table 16 and figure 16). 
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TABLE 17: ETIOLOGY OF EUVOLEMIC HYPONATREMIA 
CAUSES NO. OF PATIENTS 
MALES FEMALES 
SIADH 23 12 
ADRENAL 
INSUFFICIENCY 
1 0 
HYPOTHYROIDISM 0 4 
FLUOXETINE 0 1 
CARBAMAZEPINE 1  
 
ETIOLOGY OF EUVOLEMIC HYPONATREMIA: 
Out of 42 patients with euvolemic hyponatremia, 35 patients 
had SIADH (23 were males and 12 were females), 4 patients 
had hypothyroidism (females), 1 patient had adrenal 
insufficiency (male) and drugs causing inappropriate ADH 
secretion in 2 patients (1 male and 1 female) 
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TABLE 18: ETIOLOGY OFHYPERVOLEMIC HYPONATREMIA 
CAUSES NO. OF PATIENTS 
MALES FEMALES 
RENAL 12 9 
CARDIAC FAILURE 3 4 
CIRRHOSIS 2 0 
NEPHROTIC 
SYNDROME 
1 0 
ETIOLOGY OF HYPERVOLEMIC HYPONATREMIA: 
Out of 31 patients, 21 were due to renal causes (12 were males 
and 9 were females), 7 were due to cardiac failure (3 were 
males and 4 were females), 2 were due to cirrhosis (male) and1 
was due to nephritic syndrome (male). 
 
FIG 18: ETIOLOGY OF HYPERVOLEMIC HYPONATREMIA 
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TABLE 19: ETIOLOGY OF HYPOVOLEMIC HYPONATREMIA 
CAUSES NO. OF PATIENTS 
MALES FEMALES 
GI LOSS 8 9 
DIURETIC EXCESS 4 4 
PANCREATITIS 1 0 
RTA 1 0 
 
ETIOLOGY OF HYPOVOLEMIC HYPONATREMIA: 
Out of 27 patients, 17 were due to GI loss (8 males and 9 
females), 8 were due to diuretic excess (4 males and 4 females), 
1 was due to pancreatitis (male) and 1 was due to renal tubular 
acidosis (male). 
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TABLE 20: MEAN AGE OF HYPONATREMIC PATIENTS 
SEX MEAN AGE 
MALES 72.40±7.01 
FEMALES 72.23±6.02 
TOTAL 72.33±6.57 
MEAN AGE OF PATIENTS: 
The mean age of hyponatremic patients in this study is 72.33±6.57. 
The mean age of hyponatremic males is 72.40±7.01. 
The mean age of hyponatremic females is 72.23±6.02. 
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TABLE 21: MEAN SERUM SODIUM IN HYPONATREMIC 
PATIENTS 
SEX MEAN SERUM SODIUM 
MALES 125.01±6.56 
FEMALES 126.21±7.10 
TOTAL 125.55±6.79 
MEAN SERUM SODIUM IN HYPONATREMIC PATIENTS: 
The mean serum sodium level in hyponatremic patients in this study is 
125.55±6.79 mEq/litre 
The mean serum sodium level in males is125.01±6.56 
The mean serum sodium level in females is 126.21±7.10. 
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TABLE 22: MEAN SERUM OSMOLALITY IN HYPONATREMIC 
PATIENTS: 
SEX MEAN SERUM OSMALITY 
MALES 261.88±11.76 
FEMALES 263.63±12.23 
TOTAL 262.63±11.9 
 
MEAN SERUM OSMOLALITY IN HYPONATREMIC PATIENTS; 
The mean serum osmolality in hyponatremic patients in this study is 
262.63±11.9. 
The mean serum osmolality in males is 261.88±11.76 
The mean serum osmolality in females is 263.63±12.23 
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TABLE 23: MEAN DURATION OF ILLNESS AT 
PRESENTATION 
 
SEX MEAN DURATION OF ILLNESS 
MALES 6.1±5.09 
FEMALES 7.95±8.26 
TOTAL 6.9±6.67 
 Mean duration of illness at presentation is 6.9±6.67 
Mean duration of illness in males is 6.1±5.09 
Mean duration of illness in females is 7.95±8.26 
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DISCUSSION 
This study was conducted in a tertiary care hospital. 100 cases 
admitted in the hospital having serum sodium less than 135 mEq/litre 
were included in the study. 
The mean age of this study population is 72 with a standard 
deviation of 6. This mean age is similar to mean age of studies conducted 
by Richard h sterns et al, sudir m y rao et al etc. 
Regarding the different types of hyponatremia, In a study of 66 
elderly patients conducted by Anderson et al, in geriatric age group, 34% 
had euvolemic hyponatremia, 19 % had hypervolemic hyponatremia, 17 
% had hypovolemic hyponatremia. Various studies conducted throughout 
the world say that euvolemic hyponatremia is the commonest cause of 
hyponatremia in elderly subjects. In a study conducted by Sengupta , 
nandhini chatterjee et al in eastern part of India in 201 hyponatremic 
patients, 50.74% patients had euvolemic hyponatremia followed by 
26.86% of patients having hypervolemic hyponatremai and 22.4% 
patients having  hypovolemic hyponatremia. In this study also euvolemic 
hyponatremia appears to be the commonest cause with 42 percentages of 
patients being euvolemic, followed by hypervolemic hyponatremia of 34 
percent and next by hypovolemic hyponatremia of 27 percentage. 
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Laczi et al in their study in Hungary suggested that SIADH is the 
most common cause of hyponatremia in euvolemic subjects. A study 
conducted by CJ Thompson et al, in Dublin Ireland also suggests that 
SIADH is the commonest cause of hyponatremia in hospitalized patients. 
In this study also SIADH appears to be the most common cause of 
euvolemic hyponatemia with 35 patients out of 42 euvolemic patients 
having this syndrome.  
In this study the commonest cause of hypervolemic hyponatremia 
is renal cause with 21 out of 31 patients with hypervolemic hyponatremia. 
The other causes include congestive cardiac failure and cirrhosis. This is 
similar to the study outcomes in the study conducted by M Y rao et al in 
India. Several studies show diuretics especially thiazide, when used in 
excess and inappropriately in geriatric age group cause hyponatremia. 
This view is supported by the study conducted in Rochester university 
USA out of 200 patients with thiazide diuretic 83 patients found to have 
hyponatremia due to erroneous usage of thiazide diuretics. In this study 8 
patients were found to have hyponatremia due to excess use of diuretics. 
Out of 8 patients four were male and four were female. In seven patients 
hyponatremia is due to thiazide diuretic and in one patient hyponatremia 
is due to loop diuretic.  
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In this study GI loss accounts for the major cause of fluid loss in 
hypovolemic hyponatremia. The commonest route of fluid loss is through 
vomiting with 26 patients having vomiting and in 7 patients fluid is lost 
due to diarrhoea. Out of 40 patients with serum sodium levels below 125 
mEq/litre, 15 patients had severe CNS symptoms like seizure and coma. 
The other central nervous system symptoms are lethargy, headache, 
altered level of consciousness. The other symptoms are nausea , 
vomiting, diarrhoea and muscle cramps. Of these the commonest 
symptom is nausea with 52 patients having nausea. In this study the 
common comorbid illnesses are hypertension, diabetes mellitus, chronic 
kidney disease and coronary artery disease. Of this hypertension is 
present in 52 patients (32 are male and 20 are females), diabetes mellitus 
is present in 28 patients (15 are males and 13 are females), coronary 
artery disease is present in 18 patients (12 are males and 6 are females), 
Chronic kidney disease is present in 11 patients (6 are females and 5 are 
males). This comorbid illness is similar to the comorbid illness result 
found in study conducted by sarvanan, sudhi et al in India. In their study, 
62 percent of comorbid illness is hypertension and 51 percent were 
diabetes mellitus and 22 percent were renal failure patients and 18 
percent were coronary artery disease patients. 
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LIMITATIONS OF THE STUDY 
•  Duration of study is 6 months 
• Study population is only100 patients 
• It is a hospital based  observational  study so there is difficulty in 
identifying asymptomatic hyponatremia in community dwelling 
elderly  
• The volume status of the patient is assessed clinically which is not 
a precise method of estimation. 
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CONCLUSION 
Incidence of hyponatremia is high among elderly when compared 
to young adults. This is attributed to the fact that, when elderly persons 
are exposed to a change in environment and an altered dietary practice, 
there is impairment in their ability to maintain an optimal balance of 
water and electrolytes. The etiology of hyponatremia among geriatric age 
group is complex and it is further complicated by an unclear relationship 
between arginine vasopressin and advancing age 
Factors contributing to the development of hyponatremia in the 
elderly patients include an age associated decrease in free water excretion 
and GFR. There is sodium loss with aging. This is contributed by 
decreased action of RAAS and exaggerated action of natriuretic 
hormones. 
Development of severe hyponatremia is associated with high 
morbidity and high mortality. This is especially high with elderly 
patients.  
Hence early identification and assessment of different types of 
hyponatremia in elderly patient is very important to improve the patient 
outcome. 
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PREVALENCE AND EVALUATION OF HYPONATREMIA 
IN ELDERLY PATIENTS 
 
Name:      Age:  Sex: 
Address:      Occupation: 
 
Duration and details of illness: 
 
 
Symptoms: 
• Headache 
• Nausea  
• Vomiting 
• Diarrhea 
• Muscle weakness 
• Muscle cramps 
• Malaise 
• Altered level of consciousness 
87 
 
• Seizures 
• Coma 
PAST HISTORY: 
• Hypertension 
• Diabetes 
• CAD 
• Tuberculosis 
• Hypothyroidism 
• Hyperlipidemia 
• Ckd  
 
 
DRUG HISTORY: 
 
PERSONAL HISTORY: 
    Smoking     Alcoholism     
CLINICAL SETTING:     
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GENERAL EXAMINATION: 
 
 
 
VITALS   
 
   
VOLUME STATUS 
• PULSE 
• BLOOD PRESSURE 
• MUCUS MEMBRANES                      - DRY/MOIST 
• URINE OUTPUT 
• JVP 
• HEPATOJUGULAR REFLEX 
• COLD AND CLAMMY EXTREMITIES    - YES/ NO 
• PERIPHERAL EDEMA 
• Ascites 
• PULMONARY CONGESTION 
• CAPILLARY REFILL 
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SYSTEMIC EXAMINATION: 
CVS: 
  
RS: 
  
ABDOMEN: 
    
CNS: 
 
INVESTIGATIONS: 
Hb:             TC:  DC:  P-     L-         E-         M- Plt:        
ESR: 
Blood Glucose Random : 
Blood Urea : 
Serum Creatinine : 
Serum Electrolytes : Na+   K+  
Serum osmalalitY : 
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URINE EXAMINATION: 
Sugar : 
Deposits : 
Albumin : 
Sodium : 
 
 
 
ECG: 
 
X-RAY CHEST PA VIEW : 
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ஆராசி தகவ தா 
ெசைன இராஜி காதி அர ெபா மவமைன வ 65 வய 
ேமபட திய ேநாயாளிக" ஏப$ ேசா%ய ைறபா$ பறிய ஒ 
ஆரா)*சி நைடெப+ வகிற. 
திய ேநாயாளிக" இத ேசா%ய ைறபா$ எப எவள- 
பரவலாக இகிற எப பறி., அதகான காரண0க1 என எப 
பறி. அறி ெகா1வேத இத ஆரா)*சியி ேநாகமா. 
நீ0க" இத ஆரா)*சியி3 ப0ேகக நா0க1 வி4கிேறா. %-கைள 
அ3ல ககைள ெவளியி$ ேபாேதா அ3ல ஆரா)*சியி ேபாேதா 
த0கள ெபயைரேயா அ3ல அைடயாள0கைளேயா ெவளியிடமாேடா 
எபைத. ெதாிவி ெகா1கிேறா. 
இத ஆரா)*சியி3 ப0ேகப த0க"ைடய வி6பதி ேபாி3 தா 
இகிற. ேம7 நீ0க1 எேநர இத ஆரா)*சியி8 பிவா0கலா 
எபைத. ெதாிவி ெகா1கிேறா. 
இத சிற646 பாிேசாதைனகளி %-கைள ஆரா)*சியி ேபா அ3ல 
ஆரா)*சியி %வி3 த0க" அறிவி6ேபா எபைத. ெதாிவி 
ெகா1கிேறா. 
 
ஆரா)*சியாள9 ைகெயா6ப ப0ேகபாள9 ைகெயா6ப 
 
ேததி:  
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ஆராசி ஒத கத 
ஆரா)*சி தைல64: 
65 வய ேமபட திய ேநாயாளிக" ஏப$ ேசா%ய ைறபா$ 
பறிய ஆரா)*சி. 
 
ெபய9:  ேததி: 
வய:  உ1ேநாயாளி எ;: 
பா3:  ஆரா)*சி ேச9ைக எ;: 
 
இத ஆரா)*சியி விவர0க" அத ேநாக0க" <ைமயாக என 
ெதளிவாக விளக6பட. என விளக6பட விஷய0கைள நா 4ாி 
ெகா;$ நா என சமதைத ெதாிவிகிேற. 
ேசா%ய ைறபா% அறிறிக1 ம+ பாதி64க1 றி  
ஆரா)*சியாள9 >ற <வ விள0க6ெபேற. 
இத ேதைவயான உடபாிேசாதைன, இரத சபத6பட 
பாிேசாதைனக" மனமார சமதிகிேற. 
 
ைகெயா6ப 
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1 65 M N N N N N N N N N N Y N N N N Y Y N N 
2 78 M Y Y Y N N N N N N N Y Y N N y Y N N N 
3 66 M Y N N N N N N N N N N N N N N Y N N N 
4 81 M N N N N N N N N N N Y Y N N N Y Y N N 
5 75 M Y N N N N N N N N N N N N N N Y N N N 
6 66 F N N N N Y N N N N N N N N N N Y N N N 
7 79 F N Y Y N N N N N N N N N N N N Y N N N 
8 68 M Y Y N N N Y N N N N Y N N N N Y Y N N 
9 84 F N N N N N N N N N N N N N N N Y N N N 
10 69 F Y N N N N N N N N N Y Y Y N Y Y Y N N 
11 72 M Y Y N N N N N N N N N N N N N N Y N N 
12 72 F Y Y N N N Y N N N N N N N N N Y N N N 
13 67 M Y N Y N N N N N N Y Y Y N N N Y N N N 
14 72 F N Y N N N N N N N N N N Y N Y Y N N N 
15 66 M Y N Y N N N Y N N N N N N N N Y N N N 
16 70 M Y N N N N N N N N N Y N N N N Y N N N 
17 73 M Y N Y N N N N N N N Y N N N N Y N N N 
18 65 F Y Y N N Y N N N N N N N N N Y Y N N N 
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19 72 F N N N N N N N N N Y N N N N N N N N N 
20 66 M Y N N N N N N N N N Y Y N N N Y N N N 
21 65 M N N N N N N N N N Y Y N N N N Y N N N 
22 72 M Y N N N N N N N N Y N N N N N Y Y Y N 
23 82 M N N N N N N N N N N N N N N N Y N N N 
24 72 M N N N N N N N N N Y N N N N N Y N N N 
25 66 F Y N Y N N N N N N N N N N N N Y N N N 
26 68 M Y N N N N N N N N N N N N N N Y N N N 
27 77 F Y Y N N N N Y N N N Y N N N N Y N N N 
28 68 M N Y N N N N N N N N N N N N N Y N N N 
29 76 F Y N N N N N N N N Y Y N N N N N Y N N 
30 66 M Y Y N N N N N N N N Y Y N N N Y Y N N 
31 79 F N N N N N N N N N N N N N N N Y N N N 
32 65 M Y N N N N N N N N N Y y N N N Y Y N N 
33 66 M N Y N N N N N N N N Y Y N N N Y Y N Y 
34 72 F N Y N N N N N N N N Y Y N N N N N N N 
35 66 F N N N N N N N N N N Y Y N N Y Y Y N N 
36 75 M Y N N N N N N N N N Y N N N N Y N N N 
37 69 F Y N Y N N N N N N N Y N N N N Y N N N 
38 65 M Y N N Y N N N N N Y N N N N N Y Y N N 
39 86 M N N N N N N Y N N N Y Y N N Y Y Y N N 
40 77 F Y N N N N Y N N N N Y N N N N Y N N N 
41 78 F N N N N N N N N N Y Y Y Y N Y Y Y N N 
42 65 M N N Y N N N N N N Y N N N N N Y Y N N 
43 68 F N N N N N N N N N N N N Y N N Y Y N N 
44 75 M Y N N N N Y N N N N Y Y N N N Y Y N N 
45 66 F N N N N N N N N N Y N N N N N Y Y Y Y 
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46 72 M Y N N N N N N N N N Y Y N N N Y Y N N 
47 67 F N N N N N N N N N N Y N N N N Y Y N N 
48 65 M Y N N N N N N N N N Y N N N N Y N N N 
49 67 M N Y N N N Y N N N N N N N N N Y Y Y Y 
50 78 F Y N N N N N N N N Y Y Y N N N Y Y N N 
51 82 F Y Y N N N N N N N N N N N N N Y N N N 
52 74 F Y N N N N N Y N N N N N N N N Y Y N N 
53 82 M N Y Y N N N N N N N Y Y N N N Y Y N N 
54 91 M N N N N N N N N N Y N N N N N Y Y N Y 
55 69 F N Y N N N N N N N N N N N N N N Y Y N 
56 68 M Y N Y N N N Y N N Y N N N N N Y N N N 
57 74 F N N N N N N N N N N N N N N N Y N N N 
58 78 M Y N N N N Y N N N N N N N N N Y Y N N 
59 73 M N N N N N N N N N N Y N N N N Y N N N 
60 84 M N N N N N N N N N Y Y Y N N N Y Y N N 
61 74 F Y Y N N N Y N N N N N N N N N Y Y Y N 
62 70 M Y N N N N N N N N Y Y N N N N Y Y N N 
63 65 M N N N N N N N N N Y Y N N N N Y N Y N 
64 68 F N N Y N N N N N N Y N N N N N Y Y N N 
65 78 F N N N N N N N N N N Y N N N N Y N N N 
66 69 M Y Y N N N N N N N N N N N N N Y Y N N 
67 74 M Y N Y N N N Y N N N Y N N N N Y Y N N 
68 67 F Y N N Y N N N N N N Y N N N N Y N N N 
69 65 F Y Y N N N N N N N Y N N N N N Y N N N 
70 70 F Y Y N N N Y Y N N N N N N N N Y N N N 
71 71 M N N Y N N N N N N Y Y Y N N N Y N N N 
72 76 F N N N N N N N N N N N N N N N Y N N N 
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73 65 F N N N N Y N N N N N N N N N N Y N N N 
74 84 M Y N Y N N N N N N Y Y Y N N N Y Y N N 
75 74 M N Y N N N N N N N Y Y N N N N Y Y N N 
76 81 M Y Y N N N N N N N N Y Y Y N N Y Y Y Y 
77 67 M Y N Y N N N N N N N N N N N N Y Y N N 
78 74 M N N N N N N N N N N Y N N N N Y N N N 
79 66 M N N N N N N N N N N N N N N N Y N N N 
80 68 F Y N Y N N N N N N N N N N N N Y Y N N 
81 66 F N Y N N N Y Y N N N Y Y N N N Y Y N N 
82 71 F Y N N N N N N N N Y Y N N N N Y Y Y N 
83 84 F Y N Y N N N N N N N Y N N N N Y Y N N 
84 74 M N N N N N N N N N Y N N N N N Y Y N N 
85 86 M Y N N N N N N N N N N N N N N Y Y N N 
86 72 F N Y N N N Y N N N N N N N N Y N N N N 
87 67 F N N N N Y N N N N Y Y N N N N N N N N 
88 66 M N Y N N N N N N N Y Y N N N N Y Y N N 
89 69 F Y N N N N N N N N N Y Y Y N N Y N N N 
90 67 M Y N N N N N N N N N N N N N N Y Y N N 
91 83 M N Y N N N N N N N N Y Y N N N Y N N N 
92 67 M N N N Y N N N N N N Y N N N Y N N N N 
93 67 F N N N N N N N N N N Y Y N N N Y Y N N 
94 76 M Y Y N N N N N N N N N N N N N Y Y N N 
95 90 F N N N N N N N N N Y N N N N N Y Y Y Y 
96 76 M N N Y N N N N N N Y Y Y N N N Y Y N N 
97 72 F Y N N N N N N N N N Y Y N N N Y N N N 
98 65 M N Y N N N Y N N N N N N N N N Y N N N 
99 87 M Y N N N N N N N N N N N Y N N Y Y N N 
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100 68 M Y N N N N N N N N Y Y N N N N Y Y N N 
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1 65 M 123 32 14.95 96 256.67 Hypervolemia 8 cirrhosis 2   
2 78 M 122 38 17.76 120 257.01 Hypovolemia 18 Gi loss 3   
3 66 M 129 26 12.15 98 267.78 Euvolemia 102 SIADH 6 N N 
4 81 M 124 31 14.49 125 260.12 Euvolemia 104 SIADH 4 N N 
5 75 M 131 20 9.35 76 269.56 Euvolemia 100 SIADH 30 N N 
6 66 F 131 16 7.48 70 268.56 Euvolemia 56 HYPOTHYROIDISM 15 Y N 
7 79 F 130 30 14.02 80 269.45 Hypervolemia 18 Cardiac failure 7   
8 68 M 120 44 20.56 76 251.57 Hypervolemia 46 Renal 4   
9 84 F 132 18 8.41 69 270.84 Euvolemia 100 SIADH 7 N N 
10 69 F 118 26 12.15 84 245.01 Hypovolemia 16 Gi loss 2   
11 72 M 119 32 14.95 120 250.01 Euvolemia 78 SIADH 6 N N 
12 72 F 129 30 14.02 110 269.12 Hypervolemia 34 Renal 4   
13 67 M 130 28 13.08 90 269.67 Euvolemia 78 SIADH 4 N N 
14 72 F 123 33 15.42 124 258.4 Hypovolemia 17 Gi loss 2 N N 
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15 66 M 133 15 7.01 70 272.39 Hypovolemia 22 Diuretics 8   
16 70 M 128 45 21.03 120 270.18 Hypervolemia 43 Renal 5   
17 73 M 129 33 15.42 110 269.62 Hypervolemia 10 Cardiac failure 7   
18 65 F 131 33 15.42 113 273.78 Euvolemia 24 HYPOTHYROIDISM 30 Y N 
19 72 F 130 30 14.02 110 271.12 Euvolemia 77 SIADH 4 N N 
20 66 M 128 36 16.82 122 268.78 Hypovolemia 16 Pancreatitis 3   
21 65 M 126 42 19.63 122 265.79 Hypervolemia 18 Nephrotic 5   
22 72 M 128 40 18.69 126 269.68 Euvolemia 56 SIADH 2 N N 
23 82 M 130 32 14.95 120 272.01 Euvolemia 67 SIADH 15 N N 
24 72 M 134 15 7.01 72 274.5 Euvolemia 100 SIADH 12 N N 
25 66 F 132 20 9.35 88 272.23 Hypervolemia 14 Cardiac failure 8   
26 68 M 133 22 10.28 68 273.45 Euvolemia 89 SIADH 10 N N 
27 77 F 131 25 11.68 82 270.73 Hypovolemia 32 Diuretics 15   
28 68 M 131 28 13.08 124 273.56 Euvolemia 74 SIADH 12 N N 
29 76 F 122 32 14.95 120 256.01 Hypervolemia 36 Renal 5   
30 66 M 126 38 17.76 133 265.73 Euvolemia 66  Adrenal insuff 7 N Y 
31 79 F 134 16 7.48 76 274.89 Euvolemia 76 SIADH 14 N N 
32 65 M 119 24 11.21 111 248.17 Hypovolemia 32 RTA 3   
33 66 M 118 34 15.89 115 248.06 Hypervolemia 16 cirrhosis 2   
34 72 F 127 40 18.69 180 270.68 Hypervolemia 22 Renal 4   
35 66 F 124 38 17.76 112 260.57 Hypovolemia 18 Gi loss 2   
36 75 M 128 35 16.36 116 268.29 Hypervolemia 28 Renal 5   
37 69 F 132 32 14.95 80 273.78 Hypervolemia 15 Cardiac failure 6   
38 65 M 132 33 15.42 78 273.84 Euvolemia 98 SIADH 15 N N 
39 86 M 116 39 18.22 88 243.4 Hypovolemia 38 Diuretics 2   
40 77 F 126 47 21.96 87 264.68 Hypervolemia 56 Renal 3   
41 78 F 124 40 18.69 114 261.01 Hypovolemia 13 Gi loss 2   
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42 65 M 122 35 16.36 98 255.29 Euvolemia 76 SIADH 3 N N 
43 68 F 126 38 17.76 92 263.45 Hypovolemia 8 Gi loss 3   
44 75 M 130 45 21.03 112 273.73 Hypervolemia 45 Renal 5   
45 66 F 108 39 18.22 115 228.9 Euvolemia 76 SIADH 1 N N 
46 72 M 121 35 16.36 123 254.68 Hypovolemia 14 Gi loss 4   
47 67 F 118 46 21.5 112 249.9 Hypervolemia 56 Renal 4   
48 65 M 134 18 8.41 68 274.78 Euvolemia 66 SIADH 9 N N 
49 67 M 108 84 39.25 190 240.57 Hypervolemia 35 Renal 1   
50 78 F 118 37 17.29 114 248.51 Hypovolemia 12 Gi loss 3   
51 82 F 134 14 6.54 78 274.67 Euvolemia 87 SIADH 7 N N 
52 74 F 130 36 16.82 80 270.45 Hypovolemia 45 Diuretics 15   
53 82 M 122 42 19.63 45 253.51 Hypervolemia 45 Renal 4   
54 91 M 108 35 16.36 100 227.4 Euvolemia 78 SIADH 1 N N 
55 69 F 114 57 26.64 178 247.4 Hypervolemia 56 Renal 4   
56 68 M 129 27 12.62 121 269.23 Hypovolemia 65 Diuretics 12   
57 74 F 133 20 9.35 75 273.51 Euvolemia 67 SIADH 9 N N 
58 78 M 124 56 26.17 121 264.07 Hypervolemia 43 Renal 3   
59 73 M 129 34 15.89 111 269.84 Euvolemia 54 SIADH 6 N N 
60 84 M 132 21 9.81 78 271.84 Hypovolemia 12 Gi loss 2   
61 74 F 109 78 36.45 167 240.3 Hypervolemia 53 Renal 2   
62 70 M 116 35 16.36 120 244.51 Euvolemia 88 SIADH 3 N N 
63 65 M 126 34 15.89 121 264.4 Euvolemia 45 CARBEMAZEPINE 8 N N 
64 68 F 119 28 13.08 86 247.45 Euvolemia 97 SIADH 2 N N 
65 78 F 132 33 15.42 78 273.84 Euvolemia 45 FLUOXETINE 20 N N 
66 69 M 121 65 30.37 156 261.51 Hypervolemia 53 Renal 1   
67 74 M 126 23 10.75 122 262.62 Hypovolemia 28 Diuretics 5   
68 67 F 134 12 5.61 80 274.45 Euvolemia 66 SIADH 14 N N 
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69 65 F 132 14 6.54 120 273 Euvolemia 76 SIADH 8 N N 
70 70 F 130 45 21.03 129 274.68 Hypovolemia 45 Diuretics 4   
71 71 M 129 28 13.08 114 269 Hypovolemia 8 Gi loss 12   
72 76 F 133 20 9.35 74 273.45 Euvolemia 76 SIADH 8 N N 
73 65 F 132 21 9.81 100 273.06 Euvolemia 26 HYPOTHYROIDISM 37 Y N 
74 84 M 120 24 11.21 126 251 Hypervolemia 14 Cardiac failure 4   
75 74 M 122 28 13.08 140 256.45 Euvolemia 88 SIADH 4 N N 
76 81 M 105 29 13.55 180 224.84 Hypovolemia 15 Gi loss 2   
77 67 M 123 34 15.89 125 258.62 Hypervolemia 17 Cardiac failure 5   
78 74 M 134 16 7.48 70 274.56 Euvolemia 67 SIADH 20 N N 
79 66 M 132 18 8.41 80 271.45 Euvolemia 56 SIADH 12 N N 
80 68 F 129 20 9.35 126 268.34 Hypervolemia 18 Cardiac failure 3   
81 66 F 129 48 22.43 138 273.68 Hypovolemia 45 Diuretics 7   
82 71 F 118 35 16.36 110 247.95 Euvolemia 64 SIADH 2 N N 
83 84 F 121 25 11.68 112 252.39 Hypovolemia 12 Gi loss 3   
84 74 M 116 54 25.23 100 246.57 Hypervolemia 55 Renal 2   
85 86 M 120 34 15.89 88 250.56 Euvolemia 76 SIADH 4 N N 
86 72 F 129 53 24.77 125 273.79 Hypervolemia 55 Renal 8   
87 67 F 131 21 9.81 80 269.95 Euvolemia 45 HYPOTHYROIDISM 32 Y N 
88 66 M 127 37 17.29 100 265.73 Euvolemia 75 SIADH 3 N N 
89 69 F 124 38 17.76 112 260.57 Hypovolemia 6 Gi loss 4   
90 67 M 126 54 25.23 115 267.4 Hypervolemia 56 Renal 4   
91 83 M 124 34 15.89 123 260.51 Hypovolemia 8 Gi loss 4   
92 67 M 129 36 16.82 115 270.4 Euvolemia 93 SIADH 7 N N 
93 67 F 126 32 14.95 121 264.06 Hypovolemia 12 Gi loss 3   
94 76 M 129 45 21.03 145 273.57 Hypervolemia 45 Renal 5   
95 90 F 110 48 22.43 124 234.9 Hypervolemia 34 Renal 4   
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96 76 M 122 23 10.75 112 254.06 Hypovolemia 14 Gi loss 4   
97 72 F 132 24 11.21 88 272.89 Euvolemia 86 SIADH 5 N N 
98 65 M 129 50 23.36 143 274.29 Hypervolemia 43 Renal 7   
99 87 M 123 23 10.75 122 256.62 Hypovolemia 14 Gi loss 4   
100 68 M 133 14 6.54 102 274 Euvolemia 76 SIADH 6 N N 
 
